Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 84,502,336
  • Shares Outstanding, K 1,632,580
  • Annual Sales, $ 20,776 M
  • Annual Income, $ 1,007 M
  • 36-Month Beta 0.96
  • Price/Sales 4.05
  • Price/Cash Flow 14.66
  • Price/Book 7.13

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.56 +2.95%
on 04/25/18
63.75 -18.35%
on 03/29/18
-11.35 (-17.90%)
since 03/26/18
3-Month
50.56 +2.95%
on 04/25/18
70.05 -25.70%
on 02/16/18
-12.20 (-18.99%)
since 01/26/18
52-Week
50.56 +2.95%
on 04/25/18
70.05 -25.70%
on 02/16/18
-1.72 (-3.20%)
since 04/26/17

Most Recent Stories

More News
Bristol-Myers (BMY) Q1 Earnings Beat Estimates

Bristol-Myers (BMY) beat estimates on both counts.

BMY : 52.05 (+0.56%)
Bristol-Myer Sqb Shares Down 17.8% Since SmarTrend's Sell Call (BMY)

SmarTrend identified a Downtrend for Bristol-Myer Sqb (NYSE:BMY) on March 23rd, 2018 at $63.00. In approximately 1 month, Bristol-Myer Sqb has returned 17.83% as of today's recent price of $51.76.

BMY : 52.05 (+0.56%)
European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma

--Opdivo also now approved for two-week flat dose option with 30-minute infusions across all approved monotherapy indications in the EU

BMY : 52.05 (+0.56%)
Liquidity Services Announces Upcoming Sales for Biopharmaceutical Assets on its Go-Dove.com Global Marketplace

Liquidity Services (NASDAQ:LQDT), a global solution provider in the reverse supply chain with the world's largest marketplace for business surplus, is pleased to highlight its upcoming sales of biopharmaceutical...

LQDT : 6.25 (unch)
BMY : 52.05 (+0.56%)
Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX

Four pharma/biotech companies are set to release earnings report on Apr 26. Let's take a look into how the companies are placed ahead of the upcoming results.

JNJ : 126.63 (-0.10%)
VRTX : 155.15 (-0.33%)
NVS : 76.89 (+0.62%)
ABBV : 94.35 (+2.70%)
BMY : 52.05 (+0.56%)
ALXN : 114.00 (+7.51%)
BIIB : 273.06 (+1.34%)
Why Bristol-Myers (BMY) Might Surprise This Earnings Season

Bristol-Myers (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BMY : 52.05 (+0.56%)
Will Pfizer's (PFE) Earnings Beat Estimates Again in Q1?

While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and supply shortages in legacy Hospira products will hurt the same.

CELG : 89.50 (+0.34%)
MRK : 59.67 (+0.07%)
PFE : 36.72 (+0.11%)
BMY : 52.05 (+0.56%)
What's in the Cards for Merck (MRK) This Earnings Season?

Merck's (MRK) new products like Keytruda and Bridion are likely to drive first-quarter sales. However, headwinds remain in the form genericization of key drugs and increasing competition.

MRK : 59.67 (+0.07%)
PFE : 36.72 (+0.11%)
GSK : 39.79 (+1.71%)
BMY : 52.05 (+0.56%)
Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings?

Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q1.

CELG : 89.50 (+0.34%)
ABBV : 94.35 (+2.70%)
PFE : 36.72 (+0.11%)
BMY : 52.05 (+0.56%)
Can Allergan (AGN) Keep the Earnings Streak Alive in Q1?

While Allergan's (AGN) Q1 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products is expected to hurt sales.

MYL : 38.94 (-3.25%)
AGN : 157.12 (+0.14%)
PFE : 36.72 (+0.11%)
BMY : 52.05 (+0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious...

See More

Key Turning Points

2nd Resistance Point 52.71
1st Resistance Point 52.23
Last Price 52.05
1st Support Level 50.92
2nd Support Level 50.09

See More

52-Week High 70.05
Fibonacci 61.8% 62.60
Fibonacci 50% 60.31
Fibonacci 38.2% 58.01
Last Price 52.05
52-Week Low 50.56

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar